Loading organizations...
MyLife has raised $25.0M across 1 funding round.
Key people at MyLife.
MyLife has raised $25.0M in total across 1 funding round.
MyLife operates a comprehensive online platform designed to provide proprietary Reputation Profiles and Scores for individuals. The service aggregates publicly available information, including criminal and court records, personal reviews, and social media activity, to compile detailed profiles. These profiles aim to offer transparency, enabling users to assess others while also providing tools for individuals to monitor and manage their own public online presence.
The company was founded in 2002 by Jeffrey Tinsley, initially launching as Reunion.com before evolving to its current iteration. Tinsley’s foundational insight stemmed from the growing need for individuals to have accessible information about others in an increasingly connected digital world, driven by both social connection and personal safety concerns. This led to the development of a system to centralize and score disparate public data.
MyLife serves a broad base of individual users who seek to understand the backgrounds of people they interact with, such as friends, dates, neighbors, or relatives. It also empowers users to actively cultivate and improve their own digital reputation. The company’s long-term vision centers on enhancing safety and trust across the internet by providing a transparent layer of information, ultimately working to reduce online fraud and crime.
MyLife has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in March 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2007 | $25M Series A | — | FIN Capital | Announced |
MyLife has raised $25.0M in total across 1 funding round.
MyLife's investors include Fin Capital.
MyLife Technologies is a healthcare technology company developing innovative drug delivery systems, primarily nanoporous microneedle arrays (npMNAs) integrated into painless skin patches for vaccines and other pharmaceuticals.[1][2][3] It serves vaccine developers, healthcare providers, and non-governmental organizations by solving challenges in intradermal drug administration, such as pain, inefficiency, and high dosing requirements, enabling self-administration and potential vaccine dose sparing of 10-100 times compared to injections.[1][3] Founded in 2012 and based in Leiden, Netherlands, the private equity-stage company has raised $4.69M total, with its last round of $4M about three years ago, indicating steady but modest growth momentum in medtech innovation.[1]
MyLife Technologies emerged from pioneering research at the University of Twente (UT) in the Netherlands, where Regina Luttge and Louis Morren developed the core npMNA technology, leading to patented nanoporous microneedle arrays for transdermal delivery.[2][3] The company was formally founded in 2012 in Leiden Bio Science Park, building on this academic foundation to commercialize ceramic-based patches.[1][2] CEO Mike G.W. de Leeuw, with a background in tumor virology, business administration, and serial entrepreneurship in drug delivery startups (raising over €120M across ventures), drives strategy and funding.[2] Early traction included a key patent grant in 2019 for integrated microneedle arrays, supporting scalable manufacturing.[1] Operations head Leonie de Best brings expertise from analytical chemistry and prior medtech firms, aiding lab expansion and quality control.[2]
MyLife Technologies stands out in microneedle drug delivery through these key advantages:
MyLife Technologies rides the microneedle and transdermal delivery trend, fueled by demand for needle-free alternatives amid global vaccine equity needs and self-administration post-COVID.[1][3] Timing aligns with rising medtech investments in painless, scalable solutions for pandemics and chronic care, where traditional syringes limit access in low-resource settings.[3] Market forces like high vaccine costs and supply chain strains favor dose-sparing tech, positioning MyLife to influence healthcare ecosystems by partnering with developers and NGOs for broader adoption.[1] Its ceramic focus differentiates from polymer competitors, contributing to sustainable drug delivery innovations in Europe's biotech hub.[2][3]
MyLife Technologies is poised for expansion through partnerships and scale-up funding, targeting commercialization of npMNA patches for vaccines and beyond.[1][3] Trends like mRNA therapeutics, personalized medicine, and global health initiatives will amplify demand for efficient delivery, potentially accelerating growth if it secures larger rounds or pharma deals.[1][2] Influence may evolve from niche innovator to ecosystem enabler, enhancing vaccine access worldwide—echoing its origins in breakthrough research to transform painless, equitable healthcare.[3]
Key people at MyLife.
